18F-FDG PET/MRI for therapy response assessment in sarcoma: Comparison of PET and MR imaging results
18F-FDG PET/MRI for therapy response assessment in sarcoma: Comparison of PET and MR imaging results
Schuler, M. K.; Platzek, I.; Beuthien-Baumann, B.; Fenchel, M.; Ehninger, G. E.; van den Hoff, J.
Background: 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) has proven to be of substantial benefit in imaging of sarcoma patients. We therefore investigated the feasibility and benefit of combined PET/magnetic resonance imaging (MRI). Methods: Twelve patients with sarcoma who underwent FDG PET/MRI for staging and response assessment after chemotherapy were included. Results: Based on contrast-enhanced MRI and application of Choi criteria, therapy response was classified as stable disease in 6/12 patients (50%) and as partial remission in 6/12 patients (50%). Conclusion: In sarcoma patients, response assessment using Choi criteria based on contrast-enhanced MRI in comparison to FDG PET imaging only demonstrates slight correlation.
Keywords: Cancer imaging; Choi criteria; FDG PET/MRI; Sarcoma
Involved research facilities
- PET-Center
-
Clinical Imaging 39(2015), 866-870
Online First (2015) DOI: 10.1016/j.clinimag.2015.05.014
Cited 25 times in Scopus
Permalink: https://www.hzdr.de/publications/Publ-22243